Department of Dermatology, University of Minnesota, 516 Delaware St SE, Minneapolis, MN, 55401, USA.
University of Minnesota Medical School, Minneapolis, MN, USA.
Arch Dermatol Res. 2021 Oct;313(8):623-632. doi: 10.1007/s00403-020-02143-5. Epub 2020 Sep 23.
To analyze the prognosis of cutaneous adnexal malignancies, survival relative to surgical management, and utility of lymph-node biopsy.
Population-based study of the SEER-18 database from 1975 to 2016.
7591 patients with sweat gland carcinoma, hidradenocarcinoma, spiradenocarcinoma, sclerosing sweat duct tumor/microcystic adnexal tumor (SSDT/MAC), porocarcinoma, eccrine adenocarcinoma, and sebaceous carcinoma RESULTS: Five-year OS ranged from 68.0 to 82.6%, while 5-year DSS ranged from 94.6 to 99.0%. The majority of patients were treated with narrow (42.4%) or wide local excision (16.9%). DSS at 5 years showed that patients with stage IV had significantly poorer survival (50.3%) than I, II, or III (99.3%, 97.8%, and 89.0% respectively). 5-year OS was significantly higher for narrow excision (excision with < 1 cm margin, 78.5%) than observation (65.0%), excisional biopsy (66.8%), or wide local excision (WLE, 73.2%). Lymph-node biopsy was performed in a minority of cases (8.1%) and patients showed no significant difference in survival based on nodal status. The sensitivity and specificity of lymph-node biopsy for all malignancies were 46% and 80%, respectively. The PPV and NPV for that group were 0.46 and 0.80, respectively. Invasion of deep extradermal structures was a poor predictor of nodal positivity.
These malignancies have excellent DSS. Narrow excisions demonstrate better 5-year DSS and OS compared with WLE. Lymph-node biopsy is a poor predictor of survival in advanced stage disease and utility is limited.
分析皮肤附属器恶性肿瘤的预后、与手术治疗相关的生存情况,以及淋巴结活检的应用价值。
基于人群的 SEER-18 数据库研究,时间范围为 1975 年至 2016 年。
7591 例汗腺癌、大汗腺癌、螺旋腺瘤、硬化性汗管肿瘤/微囊性附属器肿瘤(SSDT/MAC)、派杰氏病、大汗腺腺癌和皮脂腺癌患者。
5 年 OS 范围为 68.0%至 82.6%,5 年 DSS 范围为 94.6%至 99.0%。大多数患者接受了窄切(42.4%)或广泛局部切除(16.9%)。5 年 DSS 显示,IV 期患者的生存明显较差(50.3%),而 I、II 和 III 期患者的生存率分别为 99.3%、97.8%和 89.0%。5 年 OS 窄切(切除边界<1cm,78.5%)明显高于观察(65.0%)、切取活检(66.8%)或广泛局部切除(WLE,73.2%)。淋巴结活检在少数情况下进行(8.1%),且根据淋巴结状态,患者的生存无显著差异。所有恶性肿瘤的淋巴结活检的敏感性和特异性分别为 46%和 80%。该组的阳性预测值和阴性预测值分别为 0.46 和 0.80。真皮外深层结构的侵犯是淋巴结阳性的不良预测指标。
这些恶性肿瘤具有极好的 DSS。与 WLE 相比,窄切显示出更好的 5 年 DSS 和 OS。淋巴结活检对晚期疾病的生存预测价值较低,且实用性有限。